TipRanks
Go Ultimate55% OFF

Compare Paradigm Biopharmaceuticals (PBIGF) vs. Competitors

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
PBIGFParadigm Biopharmaceuticals$0.01$107.92M-1.61-96.33%Moderate BuyUnlock the PBIGF analyst price target with TipRanks PremiumPBIGFUnlock the PBIGF top-analyst price target with TipRanks Premium
AU:ATXAmplia TherapeuticsAUD 0.08AUD 43.12M-5.03-37.78%Moderate BuyUnlock the AU:ATX analyst price target with TipRanks PremiumPBIGF vs AU:ATXUnlock the AU:ATX top-analyst price target with TipRanks Premium
AU:ACWActinogen Medical AUD 0.04AUD 162.72M-8.7523.53%Moderate BuyUnlock the AU:ACW analyst price target with TipRanks PremiumPBIGF vs AU:ACWUnlock the AU:ACW top-analyst price target with TipRanks Premium
AU:DXBDimerix LimitedAUD 0.21AUD 126.08M-4.22-57.14%―Unlock the AU:DXB analyst price target with TipRanks PremiumPBIGF vs AU:DXBUnlock the AU:DXB top-analyst price target with TipRanks Premium
AU:BOTBotanix Pharmaceuticals LimitedAUD 0.01AUD 27.63M-0.31-92.59%Moderate BuyUnlock the AU:BOT analyst price target with TipRanks PremiumPBIGF vs AU:BOTUnlock the AU:BOT top-analyst price target with TipRanks Premium
AU:RCERecce Pharmaceuticals Ltd.AUD 0.36AUD 110.10M-6.95-12.20%―Unlock the AU:RCE analyst price target with TipRanks PremiumPBIGF vs AU:RCEUnlock the AU:RCE top-analyst price target with TipRanks Premium

Performance Comparison

-100%-50%0%50%100%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
PBIGFParadigm Biopharmaceuticals0.01-0.25-95.77%
AU:ATXAmplia Therapeutics0.08-0.05-37.78%
AU:ACWActinogen Medical 0.040.0116.67%
AU:DXBDimerix Limited0.21-0.29-58.00%
AU:BOTBotanix Pharmaceuticals Limited0.01-0.12-92.31%
AU:RCERecce Pharmaceuticals Ltd.0.36-0.04-10.00%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts